Terug
26
Ook genoteerd als
CZMWY
OTC
Dagbereik
€ 29,16
€ 33,46
52-Weeksbereik
€ 26,42
€ 70,88
Volume
300
50D / 200D Gem.
€ 34,31
/
€ 49,41
Vorige Slotkoers
€ 29,16
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 18,1 | 0,4 |
| P/B | 1,2 | 2,9 |
| ROE % | 6,8 | 3,7 |
| Net Margin % | 6,3 | 3,8 |
| Rev Growth 5Y % | 7,9 | 10,0 |
| D/E | 0,1 | 0,2 |
Belangrijkste Punten
Revenue grew 7,85% annually over 5 years — modest growth
Earnings declined -20,99% over the past year
Debt/Equity of 0,06 — conservative balance sheet
Generating 200,03M in free cash flow
Cash machine — converts 141,65% of earnings into free cash flow
Capital efficient — spends only 2,08% of revenue on capex
Groei
Revenue Growth (5Y)
7,85%
Revenue (1Y)7,82%
Earnings (1Y)-20,99%
FCF Growth (3Y)20,83%
Kwaliteit
Return on Equity
6,79%
ROIC7,45%
Net Margin6,34%
Op. Margin10,02%
Veiligheid
Debt / Equity
0,06
Current Ratio2,34
Interest Coverage8,39
Waardering
P/E Ratio
18,08
P/B Ratio1,21
EV/EBITDA11,90
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,82% | Revenue Growth (3Y) | 3,26% |
| Earnings Growth (1Y) | -20,99% | Earnings Growth (3Y) | -30,27% |
| Revenue Growth (5Y) | 7,85% | Earnings Growth (5Y) | -12,08% |
| Profitability | |||
| Revenue (TTM) | 2,23B | Net Income (TTM) | 141,21M |
| ROE | 6,79% | ROA | 4,15% |
| Gross Margin | 52,76% | Operating Margin | 10,02% |
| Net Margin | 6,34% | Free Cash Flow (TTM) | 200,03M |
| ROIC | 7,45% | FCF Growth (3Y) | 20,83% |
| Safety | |||
| Debt / Equity | 0,06 | Current Ratio | 2,34 |
| Interest Coverage | 8,39 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 18,08 | P/B Ratio | 1,21 |
| P/S Ratio | 1,15 | PEG Ratio | -1,32 |
| EV/EBITDA | 11,90 | Dividend Yield | 0,02% |
| Market Cap | 2,55B | Enterprise Value | 2,66B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2,23B | 2,07B | 2,09B | 1,90B | 1,65B |
| Net Income | 141,21M | 178,73M | 290,40M | 293,91M | 236,28M |
| EPS (Diluted) | 1,61 | 2,01 | 3,25 | 3,29 | 2,64 |
| Gross Profit | 1,18B | 1,09B | 1,21B | 1,13B | 967,21M |
| Operating Income | 223,32M | 121,35M | 327,14M | 396,88M | 350,91M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3,40B | 3,39B | 3,03B | 2,82B | 2,40B |
| Total Liabilities | 1,28B | 1,34B | 860,02M | 792,73M | 718,59M |
| Shareholders' Equity | 2,12B | 2,04B | 2,16B | 2,02B | 1,66B |
| Total Debt | 132,46M | 151,35M | 155,70M | 127,90M | 121,27M |
| Cash & Equivalents | 27,27M | 20,29M | 10,60M | 7,73M | 7,44M |
| Current Assets | 1,27B | 1,21B | 1,91B | 1,79B | 1,60B |
| Current Liabilities | 543,81M | 568,84M | 561,65M | 539,32M | 448,12M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#884 of 1024
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026